Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

1.51
Delayed Data
As of May 27
 +0.05 / +3.42%
Today’s Change
1.26
Today|||52-Week Range
6.86
-59.73%
Year-to-Date

Stock Price Forecast

The 6 analysts offering 12-month price forecasts for Adaptimmune Therapeutics PLC have a median target of 6.00, with a high estimate of 9.00 and a low estimate of 2.00. The median estimate represents a +297.35% increase from the last price of 1.51.

Analyst Recommendations

The current consensus among 8 polled investment analysts is to Hold stock in Adaptimmune Therapeutics PLC. This rating has held steady since August, when it was unchanged from a Hold rating.Move your mouse over past
months for detail

 
 
 
 
 
 
 
 

Earnings and Sales Forecasts

Current Quarter

Earnings per Share
-$0.29
Sales
$6.6M
Reporting Date
Aug 04

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly -480.00%
 
 
 
 
 
 
Growthannually -610.59%
 
 
 
 
 
 

Sales

Growthquarterly 83.82%
 
 
 
 
 
 
Growthannually 270.92%
 
 
 
 
 
 
Key to the earnings and sales forecast charts.